Validation and Compliance

Jan 01, 2010
BioPharm International
Demand for new vaccines and therapies in 2010 will be offset by concerns about drug prices and product safety.
Jan 01, 2010
BioPharm International
By BioPharm International Editors
How will implementing Quality by Design strategies affect your compliance status?
Dec 01, 2009
BioPharm International
Vaccine research and development is surging, but continues to face manufacturing and regulatory challenges.
Nov 01, 2009
BioPharm International
Heightened attention to product safety issues is slowing the approval process for new therapies.
Nov 01, 2009
BioPharm International
By BioPharm International Editors
The focus on the design space will lead to a new workspace, and will affect staff in the development, manufacturing, and quality functions.
Oct 01, 2009
BioPharm International
Stiffer enforcement of quality standards aims to restore public confidence in agency actions.
Sep 01, 2009
BioPharm International
The FDA is encouraging manufacturers to invest in research and development for new vaccines and therapeutics to combat third-world diseases.
Aug 01, 2009
BioPharm International
Pressures to reduce healthcare spending generates proposals to spur competition, cut costs.
Jul 01, 2009
BioPharm International
The FDA seeks new strategies for improving the safe use of opioids and other high-risk medicines, including erythropoiesis stimulating agents.
Jul 01, 2009
BioPharm International
By BioPharm International Editors
A culture of quality that emphasizes business objectives, risk management, and the informed application of technology can improve compliance.
native1_300x100
lorem ipsum